Business Editors /Health/Medical Writers

NEWPORT BEACH, Calif.
Vaccine adjuvants are integral for use in vaccine development as
they help determine the nature of the body's immune response and aid
in directing the body to stimulate either the production of antibodies
or cell-mediated immunity. The company urges all interested parties to read these
reports to gain a better understanding of the many business and other
risks that the company faces.

mcleod kittenz

Morphotek Announces Acceptance of Investigational New Drug Application for MORAb-003 a Humanized Monoclonal Antibody for the Treatment of Advanced Ovarian Can

"
This just-published 284-page, comprehensive report includes the
very latest etiological and U .

mixon diagnosed

EXTON, Pa. epidemiological data on the most
prevalent 11 disease categories.1016/j.D. "While the development of cancer
vaccines is promising, we believe it may be significantly strengthened
by the use of GPI-0100 to induce a stronger immune response in cancer
patients. The present study
shows that GPI-0100 appears to be safe and to stimulate a strong
immune response in man, warranting its use in further vaccine studies. Certain saponins, naturally occurring glycosides found in
many plants, have been shown to stimulate both a humoral and
cell-mediated immunity, but their toxicity and instability limits
their use in vaccines.

About Australian Cancer Technology (www. More detailed
information on these and additional factors that could affect the
company's operating and financial results are described in the
company's annual reports filed or to be filed with the Australian
Stock Exchange.

pancreatic ended

MORAb-003 is a monoclonal antibody that has high specificity for a number
of different cancers, including ovarian, breast, colorectal, lung, renal, and
brain.

com.01.
Further clinical trials at Memorial Sloan-Kettering are being
planned for melanoma, neuroblastoma , breast cancer, ovarian cancer and
chronic myeloid leukemia patients using the GPI-0100 adjuvant .

ewing memorials

The antibody targets a receptor
present at high density on cancer cells, and offers a very high degree of
specificity for malignant tissues.morphotek. Sass, Executive Vice President and Chief Operating Officer,
Morphotek, Inc. Disease Incidence and Prevalence.

AustCancer Vaccine Adjuvant Demonstrates Enhanced Immune Response in Prostate Cancer Patients

pancreatic neuroblastoma

In pre-clinical cancer models the antibody has demonstrated that it
can efficiently kill chemo-refractory tumors and suppress growth in xenograft
studies.

The Most Prevalent and Costly Diseases in the U.S. Detailed in a New Disease Incidence and Prevalence Report Published by Medtech Insight

"
In the prostate cancer patients treated, all of the vaccines
containing GPI-0100 were found to be safe.S.

mixon rhabdomyosarcoma

, Morphotek, Inc.

pancreatic cns

medtechinsight. This is the first report of the
use of GPI-0100 in humans. The
company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information ,
future events or otherwise.

mcleod kittenz

Worldwide, more than 182,000 new patients will be diagnosed with
this form of cancer (World Health Organization).S. The results of the study
data were reported in an electronic publication of the journal Vaccine
(doi:10. Cohorts of five patients received vaccine
formulations containing the same amount of conjugate but with
escalating doses (100, 300, 1,000 or 3,000ug) of GPI-0100 to assess
safety.

neuroblastoma prematurely

Morphotek is also marketing an exciting new antibody platform for
developing high-quality, fully human therapeutic antibodies that significantly
reduces the royalty burdens associated with current technologies.----Some of the
most prevalent and costly diseases and disorders in the United States
include surgical and traumatic wounds, breast, prostate and colon
cancer, cardiovascular and peripheral vascular disease, diabetes,
osteoarthritis, osteoporosis, Alzheimer's disease, depressive
disorder, cataracts, endometriosis, infertility, prostate disease,
incontinence, sleep apnea and asthma, among others. Overall, patients
receiving GPI-0100 had significantly less pain or inflammation at the
injection sites and fewer systemic symptoms compared to patients
receiving QS-21 who had similar antibody titers.

ovarian heroic

The Phase I clinical
study is designed as an open label single dose escalation safety study in
patients with chemo-refractive ovarian cancer. "We are in the late stages of
development for a second monoclonal antibody, MORAb-009, which is an antibody
that targets a high percentage of pancreatic cancers and other difficult to
treat malignancies.

Business Editors/Health/Medical Writers

SYDNEY, Australia + SAN DIEGO----

Results from a Phase I Study Conducted at Memorial Sloan-Kettering
Cancer Center Utilizing GPI-0100 Published in Vaccine

Australian Cancer Technology (AustCancer) (ASX:ACU) today
announced that Phase I clinical studies utilizing the company's lead
vaccine immunostimulant GPI-0100 demonstrated enhanced immune response
in patients with relapsed prostate cancer.

mixon ewing

Phone: 610-423-6106

kittenz roscoe

"An unmet medical need exists for patients with advanced, chemo-refractory
ovarian cancer," stated Nicholas Nicolaides, President and Chief Executive
Officer. Patients had no evidence of disease except for rising
PSA levels.
GPI-0100 is AustCancer's lead compound for use in the active
immunotherapy of cancer and some chronic infectious diseases. The company also
markets revisys(TM), a branded line of medical nutritionals designed
for people with special needs, including those undergoing cancer
treatments .

rhabdomyosarcoma remembrances

Morphotek(R), Inc.vaccine. In addition, a
Phase I folate kidney cancer vaccine using GPI -0100 is being studied
by Endocyte at Baylor University, Texas.

Tributes in memory of the courageous people who have lost their battle with cancer.

remembrances painful

"
Ovarian cancer ranks fourth in cancer deaths among women, accounting for
more deaths than any other cancer of the reproductive system (American Cancer
Society). A
semi-synthetic compound derived from saponins, GPI-0100 acts by
up-regulating the body's immune system and stimulating both humoral
and an effective T-cell immunity with CTL production .

mixon kittenz

Sass, Executive Vice President and
Chief Operating Officer of Morphotek. These include: 1) acute and chronic
skin wounds including illness-related wounds, pressure ulcers, and
surgical and traumatic wounds; 2) blood disorders including anemia and
hemophilia; 3) cancer, including bladder, breast , bronchus and lung,
cervical/uterine, colon/rectal, leukemia, lymphoma, nervous system,
oral, ovarian, pancreatic, prostate, and skin cancer; 4)
cardiovascular diseases and disorders including atherosclerosis,
congestive heart failure, hypercholesterolemia, hypertension, and
ischemic heart disease; pacing disorders including arrhythmias and
sudden cardiac death, and valvular heart disease; and 5) human
immunodeficiency virus (HIV) and acquired immune deficiency syndrome
(AIDS).
This detailed reference source also includes 109 detailed
exhibits. For more on the company's
products and services, please see www.
The impact of immunotherapies on biomarkers such as PSA and their
effects on disease progression has yet to be conclusively validated. AustCancer's Pentrys(TM)
anti-cancer vaccine is being evaluated in prostate cancer patients in
Phase IIb clinical studies and the company is advancing immune
enhancing adjuvants in three Phase I cancer trials.

mcleod sharron

S.
For further information visit http://www., Medtech Insight is
the leading provider of business information and market intelligence
for the medical technology marketplace. The dose-escalation study sought to determine the optimal
(in terms of antibody response) and safe dose range of the adjuvant
GPI-0100 when used with a bivalent conjugate vaccine (glycosylated
MUC-2-KLH and Globo H-KLH). AustCancer is traded on the Australian Stock Exchange
(ASX) under the symbol ACU.

sharron kittenz

In 2005, it is estimated that there will be 22,220 new cases of
ovarian cancer in the U.

CONTACT:
Dr.com

The Phase I study, led by Susan Slovin, M.
Subsequent studies in 14 patients at doses of 1,000, 3,000 and
5,000ug were carried out using a more purified GPI-0100.
"Currently, there is no standard of care for patients who have
rising PSA levels after primary therapy failed," said Paul Hopper,
AustCancer's chief executive officer.

patty memorials

and approximately 16,000 women will die from the
disease . is a biotechnology company focused on the generation of
proprietary organisms for product discovery and development.medtechinsight.com/ReportA700., assistant professor
of medicine at Memorial Sloan -Kettering Cancer Center, included
patients with progressive prostate disease after primary surgery or
radiotherapy. Another
cohort of 9 patients was enrolled in a second trial with the same
vaccine using the competitive saponin adjuvant QS-21 at 100ug, a dose
established in earlier trials. Patients receiving the two GPI-0100 batches showed
comparable grade I local reaction but slightly less grade II local
reactivity using the more purified GPI-0100.com.

Forward-Looking Statements

Statements contained in this press release that are not historical
information are forward-looking statements as defined within the
Private Securities Litigation Reform Act of 1995. Such potential risks and
uncertainties relate, but are not limited, to the results of clinical
trials, product demand and market acceptance, the impact of
competitive products and pricing, effectiveness and pace of current
and future product development, and regulatory approval.

ended courageous

"In pre-clinical studies MORAb -003 has been shown to be active
against chemo-refractory ovarian tumors."
"This is the first of several antibodies in our product portfolio that the
company plans on advancing into clinical development for cancer, inflammation
and infectious diseases," added Philip M. Most adjuvants primarily elicit only a
humoral response and are not capable of stimulating the production of
cytotoxic T lymphocytes (T-cells), potentially limiting their use in
protection against certain diseases such as cancer and different viral
infections. The historical results achieved by the
company are not necessarily indicative of its future prospects.

sarcoma ovarian

This
versatile technology has been successfully applied to microbes, plants, and
mammals to yield genetically diverse offspring that are suitable for
pharmaceutical and agricultural product development in the areas of antibody
and protein therapeutics , high-titer protein manufacturing, and drug target
discovery. Medtech Insight
announces the publication of a new Market + Technology Report
examining these and many other increasingly burdensome health
problems, including current incidence and prevalence figures for 80
separate diseases/disorders for the years 1996-2001, 2003, and 2004
when available, titled "U. Serologic responses, flow
cytometric analysis and the impact on PSA levels were evaluated in all
patients.

memorials pancreatic

We will file an IND by the end of this year. The Company has
a validated and patented platform technology called morphogenics that rapidly
enhances the natural process of genetic evolution within a targeted host to
yield variants with novel, commercially important output traits. Internally,
Morphotek employs its morphogenics technology to develop optimized therapeutic
antibodies for the treatment of cancer, inflammatory and infectious diseases.S.072). The company has established a Level 1 ADR
stock program in the U . trading under the symbol AUCJY and also is
listed on the Xetra exchange, the electronic trading system of the
Frankfurt Stock Exchange, trading under the symbol CBS.

patty mixon

We look forward to updating the progress
of this antibody as it advances through clinical trials. Philip M.html

Now a division of Windhover Information Inc.2005.au

Australian Cancer Technology (AustCancer) is an international
biotechnology company developing a broad oncology-related product
portfolio.

gastrointestinal memorials

Chapter 6 of this thoroughly researched report details metabolic
diseases and disorders including cholelithiasis , chronic kidney
disease, diabetes mellitus, end-stage renal disease, and urolithiasis. We are very encouraged by the results found in this study
and intend to evaluate GPI-0100 further in several vaccine development
projects including cancer and infectious agent vaccines. AustCancer has acquired the North American marketing rights
for RP101, a promising pancreatic cancer drug currently in Phase II
clinical studies through a subsidiary company, Resistys Inc, a joint
venture with Bioaccelerate of New York.

rhabdomyosarcoma prematurely

today announced that
the United States Food and Drug Administration has accepted its
Investigational New Drug (IND) Application for treatment of advanced ovarian
cancer with MORAb -003, a humanized monoclonal antibody.
Also covered is 7) musculoskeletal diseases including osteoarthritis
and rheumatoid arthritis, carpel tunnel syndrome, Duchenne's muscular
dystrophy, and osteoporosis; 8) neurologic diseases and disorders
including Alzheimer's disease, amyotrophic lateral sclerosis (ALS),
cerebrovascular diseases including arteriovenous malformation,
cerebral aneurysm and stroke , epilepsy, Huntington's disease,
hydrocephalus, multiple sclerosis, myasthenia gravis, and Parkinson 's
disease; psychiatric disorders including bipolar disorder, depression,
and schizophrenia; 9 ) ophthalmologic diseases including cataracts and
glaucoma; 10) reproductive and genitourinary disorders including
endometriosis, male and female infertility, benign prostatic
hyperplasia (BPH), erectile dysfunction, and urinary incontinence; and
11) respiratory diseases and disorders including adult respiratory
distress syndrome, apnea, asthma, chronic obstructive pulmonary
diseases such as chronic bronchitis and emphysema, cystic fibrosis,
infectious diseases including pneumonia and tuberculosis , pleural
disorders including empyema, pleural effusion and pneumothorax,
pulmonary embolism, respiratory failure, and restrictive pulmonary
diseases. A full table of contents and ordering information can be
viewed at http://www. Different from
certain immune stimulatory saponins, GPI-0100 has superior stability
and safety profile, making it an ideal candidate for the development
of novel therapeutics or preventive vaccines.
GPI-0100 currently is being evaluated in a Phase I study in
combination with HER-2 vaccine for breast cancer at the University of
Alabama at Birmingham Comprehensive Cancer Center.austcancer. Such forward-looking
statements are subject to risks and uncertainties that could cause
Australian Cancer Technology's ("company") actual results to differ
materially from those projected or implied.

subsequent ewing

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)